Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Oragenics received a deficiency letter from NYSE American on August 26, 2026, stating it is not in compliance with continued listing standards due to insufficient stockholders' equity. The company has 45 days to submit a compliance plan and must regain compliance by February 25, 2028, to avoid delisting. On the clinical front, the company has dosed nine participants across three active Australian sites in its Phase IIa trial for ONP-002, its lead intranasal candidate for mild traumatic brain injury.
Key figures
- Active sites
- 3
- Participants dosed
- 9
- Ind submission target
- end of 2026
- Final compliance deadline
- February 25, 2028
- Plan submission deadline days
- 45
- Equity threshold section 1003 a ii
- $4 million
- Equity threshold section 1003 a iii
- $6 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.